Paul T. Quinlan's Insider Trades & SAST Disclosures
Paul T. Quinlan's most recent trade in Oruka Therapeutics Inc. was a trade of 162,500 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 22, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Paul T. Quinlan.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Oruka Therapeutics Inc. | Paul T. Quinlan | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2025 | 162,500 | 162,500 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 233,176 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 215,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 107,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 105,625 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 41,824 | 0 (0%) | 0% | - | Common Stock | |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 28,438 | 0 (0%) | 0% | - | Common Stock | |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 22,167 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2024 | 41,824 | 8,872 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.89 per share. | 13 Mar 2024 | 41,824 | 70,262 (0%) | 0% | 7.9 | 329,991 | Common Stock |
| Cymabay Therapeutics Inc | T. Quinlan Paul | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 105,625 | 105,625 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Quinlan T. Paul | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 28,438 | 28,438 (0%) | 0% | 0 | Common Stock | |
| Cymabay Therapeutics Inc | Quinlan T. Paul | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 16 Jan 2024 | 5,000 | 5,000 (0%) | 0% | 2.9 | 14,700 | Common Stock |
| Cymabay Therapeutics Inc | Quinlan T. Paul | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 5,000 | 107,000 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | T. Paul Quinlan | General Counsel | Sale of securities on an exchange or to another person at price $ 23.58 per share. | 16 Jan 2024 | 5,000 | 0 (0%) | 0% | 23.6 | 117,898 | Common Stock |
| Cymabay Therapeutics Inc | Quinlan T. Paul | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 15 Dec 2023 | 5,000 | 5,000 (0%) | 0% | 2.9 | 14,700 | Common Stock |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Sale of securities on an exchange or to another person at price $ 21.98 per share. | 15 Dec 2023 | 5,000 | 0 (0%) | 0% | 22.0 | 109,903 | Common Stock |
| Cymabay Therapeutics Inc | Paul Quinlan T. | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2023 | 5,000 | 112,000 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 15 Aug 2023 | 5,000 | 5,000 (0%) | 0% | 2.9 | 14,700 | Common Stock |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 5,000 | 180,000 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Sale of securities on an exchange or to another person at price $ 11.91 per share. | 15 Aug 2023 | 5,000 | 0 (0%) | 0% | 11.9 | 59,551 | Common Stock |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Sale of securities on an exchange or to another person at price $ 11.81 per share. | 14 Jul 2023 | 5,000 | 0 (0%) | 0% | 11.8 | 59,050 | Common Stock |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jul 2023 | 5,000 | 185,000 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 14 Jul 2023 | 5,000 | 5,000 (0%) | 0% | 2.9 | 14,700 | Common Stock |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Sale of securities on an exchange or to another person at price $ 10.05 per share. | 30 Jun 2023 | 5,000 | 0 (0%) | 0% | 10.1 | 50,250 | Common Stock |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 5,000 | 190,000 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 30 Jun 2023 | 5,000 | 5,000 (0%) | 0% | 2.9 | 14,700 | Common Stock |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Sale of securities on an exchange or to another person at price $ 10.37 per share. | 15 May 2023 | 5,000 | 0 (0%) | 0% | 10.4 | 51,831 | Common Stock |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2023 | 5,000 | 195,000 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 15 May 2023 | 5,000 | 5,000 (0%) | 0% | 2.9 | 14,700 | Common Stock |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 215,000 | 215,000 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 200,000 | 200,000 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 22,167 | 22,167 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Paul T. Quinlan | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Oct 2020 | 275,000 | 275,000 | - | - | Employee Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges